RxDoctor Payments Data

Debra Dube, MD

Internal Medicine · Longwood, FLNPI 1770697930

Payments from drug & device makers

$28,477in general payments, 2019–2025

Across 898 payments — averaging $31.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$13K
  • AstraZeneca$3K
  • Novo Nordisk$2K
  • AbbVie$2K
  • Boehringer Ingelheim$1K
  • Amgen$927
  • plus $7K from 46 others

What the payments were for

  • Speaking & faculty fees$11,45040%
  • Food & beverage$16,90959%
  • Education$1180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,477 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$69,949
Medicare patients
210
Services billed
690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$112,782
JardianceEmpagliflozin75$89,499
TrulicityDulaglutide63$80,373
OzempicSemaglutide57$72,355
EliquisApixaban62$61,337
RybelsusSemaglutide16$31,114
FarxigaDapagliflozin Propanediol20$19,335
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$15,678
SynthroidLevothyroxine Sodium129$14,063
Liothyronine Sodium159$7,215
Rosuvastatin Calcium409$5,065
PremarinEstrogens, Conjugated15$4,175
DuleraMometasone/Formoterol11$3,721
Verapamil SrVerapamil Hcl12$3,286
UnithroidLevothyroxine Sodium61$3,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$12,695$193,156154 claims
Novo NordiskOzempic, Rybelsus$2,422$103,46973 claims
Boehringer IngelheimJardiance$1,023$89,49975 claims
PfizerEliquis, Premarin$342$65,51277 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,870$35,01337 claims
AbbVieSynthroid$1,850$14,063129 claims
Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium$262$5,269285 claims
MerckDulera$122$3,72111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Longwood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →